Parties
Company
Recursion Pharmaceuticals, Inc.
Company
Valence Discovery
Recursion Pharmaceuticals, Inc. completed the acquisition of Valence Discovery on May 16, 2023, for a total value of $47.5 million. In this transaction, Recursion Pharmaceuticals agreed to issue up to approximately 8.2 million Class A Shares. These shares comprised of Recursion's Class A common stock, shares of a Recursion subsidiary exchangeable for Recursion’s Class A common stock, and the assumption of certain outstanding Valence options. The agreement also included a provision allowing Recursion to offer nominal cash consideration to Valence and Cyclica shareholders, as an alternative to the exchangeable shares or Recursion Class A common stock, although this would only occur under specific, limited circumstances. The overall purchase price was subject to adjustments.
Deal Type
Merger & AcquisitionIndustry
HealthcareTransaction
$ 63,951,862Deal Status
ClosedClosing Date
16 May 2023